Raymond James analyst Tiago Fauth raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $239 from $227 and keeps an Outperform rating on the shares. JAZZ is up 25% year-to-date as investors have begun to digest the idea that the company is in the early innings of a transformation from a spec pharma story to an innovation-led biotech story, particularly following zani’s highly competitive readout in 1L GEA and priority review, the analyst says in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals reports Q1 adjusted EPS $6.34, consensus $4.66
- Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.45B
- JAZZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jazz Pharmaceuticals’ sBLA for Ziihera combination in GEA accepted by FDA
- Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays